Abstract
Neonatal hypoxic-ischemic (HI) injury still remains an important issue as it is a frequent cause of neonatal death and life-long neurobehavioral and cognitive dysfunction. In spite of the decades of research which led us to a better knowledge of the pathological mechanism of hypoxic-ischemic brain injury, the clinical use of potential neuroprotective drugs (including, among others, excitatory amino acids antagonists, free radical inhibitors and scavengers, growth factors, xenon, cannabinoids, anti-inflammatory and anti-apoptotic agents) became avoided owing to insufficiency and /or treatment-induced undesirable side effects. The only available effective treatment, hypothermia, neither provides complete brain protection nor stimulates the repair necessary for neurodevelopmental outcome. This fact brings about increased interest in alternative methods of therapy, such as regenerative medicine using stem cells. Growing number of in vivo preclinical studies revealed that mesenchymal stem cells as well as human cord blood cells may improve functional outcome after HI insult and may represent a new beneficial treatment modality for infants developing hypoxic-ischemic encephalopathy. In this review we briefly highlight the present and potential forthcoming therapeutic treatments aimed at attenuation of the detrimental effects of neonatal hypoxia-ischemia.
Keywords: Brain damage, hypoxia-ischemia, neuroprotection, neurogenesis, stem cells, transplantation.
Current Pharmaceutical Design
Title:Current and Experimental Pharmacological Approaches in Neonatal Hypoxic- Ischemic Encephalopathy
Volume: 21 Issue: 11
Author(s): Teresa Zalewska, Joanna Jaworska and Malgorzata Ziemka-Nalecz
Affiliation:
Keywords: Brain damage, hypoxia-ischemia, neuroprotection, neurogenesis, stem cells, transplantation.
Abstract: Neonatal hypoxic-ischemic (HI) injury still remains an important issue as it is a frequent cause of neonatal death and life-long neurobehavioral and cognitive dysfunction. In spite of the decades of research which led us to a better knowledge of the pathological mechanism of hypoxic-ischemic brain injury, the clinical use of potential neuroprotective drugs (including, among others, excitatory amino acids antagonists, free radical inhibitors and scavengers, growth factors, xenon, cannabinoids, anti-inflammatory and anti-apoptotic agents) became avoided owing to insufficiency and /or treatment-induced undesirable side effects. The only available effective treatment, hypothermia, neither provides complete brain protection nor stimulates the repair necessary for neurodevelopmental outcome. This fact brings about increased interest in alternative methods of therapy, such as regenerative medicine using stem cells. Growing number of in vivo preclinical studies revealed that mesenchymal stem cells as well as human cord blood cells may improve functional outcome after HI insult and may represent a new beneficial treatment modality for infants developing hypoxic-ischemic encephalopathy. In this review we briefly highlight the present and potential forthcoming therapeutic treatments aimed at attenuation of the detrimental effects of neonatal hypoxia-ischemia.
Export Options
About this article
Cite this article as:
Zalewska Teresa, Jaworska Joanna and Ziemka-Nalecz Malgorzata, Current and Experimental Pharmacological Approaches in Neonatal Hypoxic- Ischemic Encephalopathy, Current Pharmaceutical Design 2015; 21 (11) . https://dx.doi.org/10.2174/1381612820999141029162457
DOI https://dx.doi.org/10.2174/1381612820999141029162457 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
From Dual Peroxisome Proliferator Activated Receptor Agonists to Selective Peroxisome Proliferator Activated Receptor Modulators
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Inflammatory Caspases: Targets for Novel Therapies
Current Pharmaceutical Design Current Pharmacological Approaches to Prevent and Treat Post- Menopausal Osteoporosis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Why are Excipients Important to Neonates?
Current Pharmaceutical Design The Effects of Obesity on the Cerebral Vasculature
Current Vascular Pharmacology Carotid Artery Disease: Current Concepts on Endothelial Dysfunction and Matrix Remodeling
Current Drug Therapy Cerebral Ischemia and Angiogenesis
Current Neurovascular Research The Role of Apoptotic Pathways in Alzheimers Disease Neurodegeneration and Cell Death
Current Alzheimer Research Revised Roberts Cytoprotection and Adaptive Cytoprotection and Stable Gastric Pentadecapeptide BPC 157. Possible Significance and Implications for Novel Mediator
Current Pharmaceutical Design Progressive Brain Damage and Alterations in Dendritic Arborization after Collagenase-Induced Intracerebral Hemorrhage in Rats
Current Neurovascular Research Commentary: Neurorestoratology: A Concept and Emerging Discipline in the Treatment of Neurological Disorders
CNS & Neurological Disorders - Drug Targets Clinical Applications of Non-Antimicrobial Actions of Tetracyclines in Inflammatory Diseases
Current Drug Therapy Advanced Approaches of Bioactive Peptide Molecules and Protein Drug Delivery Systems
Current Pharmaceutical Design Role of Serum and Glucocorticoid-Inducible Kinase (SGK)-1 in Senescence: A Novel Molecular Target Against Age-Related Diseases
Current Medicinal Chemistry Non-adenosine Nucleoside Inosine, Guanosine and Uridine as Promising Antiepileptic Drugs: a Summary of Current Literature
Mini-Reviews in Medicinal Chemistry Conference Report [IANR V and 9th GCNN Conference with 4th ISCITT Symposium]
CNS & Neurological Disorders - Drug Targets The Role of Bax/Bcl-2 and Pro-Caspase Peptides in Hypoxia/Reperfusion-Dependent Regulation of MAPKERK: Discordant Proteomic Effect of MAPKp38
Protein & Peptide Letters Silencing the Brain May be Better than Stimulating it. The GABA Effect
Current Pharmaceutical Design Serum S-100B Protein as A Biochemical Marker of Brain Injury: A Review of Current Concepts
Current Medicinal Chemistry Molecular Links Between Endothelial Dysfunction and Neurodegeneration in Alzheimer's Disease
Current Alzheimer Research